首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1616378

生物功能晶片(Organs-On-Chips)的全球市場規模:各終端用戶，各用途，各類型，各地區，範圍及預測

Global Organs-On-Chips Market Size By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes), By Application (Physiological Model Development, Drug Discovery), By Type (Liver, Heart), By Geographic Scope And Forecast

出版日期: 2024年10月31日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

晶片器官市場規模及預測

2024 年，晶片器官市場規模為 921.6 億美元，預計 2024 年至 2031 年複合年增長率為 10.56%，到 2031 年將達到 1915 億美元。器官晶片是一種微流體裝置，可以在微型尺度上再現人體器官的結構和功能。這些晶片包含模擬器官生理環境的活體人體細胞，使研究人員能夠在受控環境中研究器官功能、疾病機制和藥物反應。透過提供比傳統細胞培養或動物實驗更準確的模型，器官晶片為人類生物學提供了寶貴的見解。

生物功能晶片（Organs-On-Chips）的應用範圍廣泛，正在對各個領域產生影響。它主要用於藥物開發和毒性測試，使製藥公司能夠評估新化合物對人體組織的影響，而無需僅依賴動物模型。

此外，這些設備還可用於研究疾病過程，使研究人員能夠在更生理相關的背景下研究癌症、心血管疾病和神經退化性疾病等疾病。

全球器官晶片市場動態

塑造全球晶片器官市場的主要市場動態

主要驅動因素

微加工的進展：

微加工技術的創新將增強晶片上器官的設計和功能，提高其準確性和適用性。根據美國國家標準與技術研究院 (NIST) 2024 年 2 月發布的報告，2020 年至 2023 年間，生物醫學應用微加工研究的投資增加了 35%。

對個人化醫療的需求不斷增加：

向個人化醫療的轉變正在推動人們對用於藥物測試和疾病建模的器官晶片的興趣，以提供客製化的治療解決方案。 2024年1月，美國食品藥物管理局（FDA）報告稱，2023年個人化醫療的核准數量較前一年增加28%。

監理支援：

藥物開發和毒性測試監管機構對晶片器官的認可度不斷提高，正在加速其在製藥和生物技術行業的採用。例如，2024 年 1 月，歐洲藥品管理局 (EMA) 發布了在臨床前藥物測試中使用器官晶片的新指南，顯示監管過程中對該技術的接受度不斷提高。

主要問題

開發成本高：

器官晶片所需的複雜製造流程和技術可能會導致巨大的研發成本。

技術限制：

目前的模型可能無法完全再現人體器官的複雜性，限制了它們在某些研究領域的可靠性和適用性。

監理挑戰：

在藥物測試中推動器官晶片的接受和標準化不斷發展的監管環境將成為廣泛採用的障礙。

主要趨勢

與人工智慧和機器學習整合：

引入人工智慧技術將增強數據分析和預測建模，提高藥物測試和疾病研究中器官晶片系統的準確性。根據美國國立衛生研究院 (NIH) 2024 年 1 月發布的報告，2021 年至 2023 年間，人工智慧與晶片器官系統結合使用將增加 58%。

多重器官模型的擴展：

人們對多器官晶片的興趣日益濃厚，可以實現更複雜的相互作用並更好地模擬人體生理學，從而推進藥物療效和安全性的評估。例如，2024 年 1 月，TissUse GmbH 宣布推出 "晶片人體" 平台，該平台允許多達 10 個不同的器官模型與一個微流體設備連接。

關注疾病模型：

對特定疾病模型的需求不斷增長，正在推動器官晶片的創新，並促進對癌症、心血管疾病和神經退化性疾病等疾病的研究。例如，2024 年 2 月，Emulate, Inc. 宣布與阿茲海默症協會合作開發一款專門用於模擬神經退化性疾病的 "大腦晶片" 。

Organs-On-Chips Market size was valued at USD 92.16 Billion in 2024 and is projected to reach USD 191.5 Billion by 2031, growing at a CAGR of 10.56% from 2024 to 2031. Organs-on-chips are microfluidic devices that replicate the structure and function of human organs at a miniature scale. These chips contain living human cells arranged in a way that mimics the physiological environment of the organs they represent, enabling researchers to study organ functions, disease mechanisms, and drug responses in a controlled setting. By providing a more accurate model than traditional cell culture or animal testing, organs-on-chips offer valuable insights into human biology.

The applications of organs-on-chips are diverse and impactful across various fields. They are primarily used in drug development and toxicity testing, allowing pharmaceutical companies to assess the effects of new compounds on human tissues without relying solely on animal models.

Additionally, these devices can be used to study disease processes, enabling researchers to investigate conditions like cancer, cardiovascular diseases, and neurodegenerative disorders in a more physiologically relevant context.

Global Organs-On-Chips Market Dynamics

The key market dynamics that are shaping the global organs-on-chips market include:

Key Drivers

Advancements in Microfabrication:

Innovations in microfabrication technologies enhance the design and functionality of organs-on-chips, improving their accuracy and applicability. According to a report by the National Institute of Standards and Technology (NIST) published in February 2024, investments in microfabrication research for biomedical applications increased by 35% between 2020 and 2023.

Rising Demand for Personalized Medicine:

The shift towards personalized medicine fuels interest in organs-on-chips for drug testing and disease modeling, providing tailored therapeutic solutions. The U.S. Food and Drug Administration (FDA) reported in January 2024 that the number of personalized medicine approvals increased by 28% in 2023 compared to the previous year.

Regulatory Support:

Increasing recognition of organs-on-chips by regulatory bodies for drug development and toxicity testing accelerates adoption in pharmaceutical and biotech industries. For instance, in January 2024, the European Medicines Agency (EMA) released new guidelines for the use of organs-on-chips in preclinical drug testing, signaling growing acceptance of this technology in regulatory processes.

Key Challenges:

High Development Costs:

The complex manufacturing processes and technology required for organs-on-chips can lead to significant research and development expenses.

Technical Limitations:

Current models may not fully replicate the complexity of human organs, limiting their reliability and applicability in certain research areas.

Regulatory Challenges:

Navigating the evolving regulatory landscape for acceptance and standardization of organs-on-chips in drug testing poses hurdles for widespread adoption.

Key Trends

Integration with AI and Machine Learning:

The incorporation of AI technologies enhances data analysis and predictive modeling, improving the accuracy of organ-on-chip systems in drug testing and disease research. According to a report by the National Institutes of Health (NIH) published in January 2024, the use of AI in conjunction with organ-on-chip systems increased by 58% between 2021 and 2023.

Expansion of Multi-Organ Models:

Increasing interest in multi-organ chips allows for more complex interactions and better simulation of human physiology, advancing drug efficacy and safety assessments. For instance, in January 2024, TissUse GmbH unveiled their "Human-on-a-Chip" platform, capable of connecting up to ten different organ models in a single microfluidic device.

Focus on Disease Modeling:

Growing demand for disease-specific models drives innovation in organs-on-chips, facilitating research on conditions like cancer, cardiovascular diseases, and neurodegenerative disorders. For instance, in February 2024, Emulate, Inc. announced a collaboration with the Alzheimer's Association to develop a "Brain-Chip" specifically designed to model neurodegenerative disorders.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Organs-On-Chips Market Regional Analysis

Here is a more detailed regional analysis of the global organs-on-chips market:

North America

North America is dominating the organs-on-Chips market, driven by substantial investments in research and development, a robust biotechnology sector, and supportive regulatory frameworks. The U.S. National Institutes of Health (NIH) reported allocating USD 89 Million in fiscal year 2023 to support research on microphysiological systems, including organs-on-chips, highlighting the region's commitment to advancing this technology. This significant funding has accelerated the development and adoption of organs-on-chips across pharmaceutical companies, academic institutions, and research organizations in North America.

The region's dominance is further solidified by the presence of leading market players and a growing emphasis on reducing animal testing in drug development. According to the U.S. Food and Drug Administration (FDA), the average cost to develop a new drug exceeds USD 2.6 Billion, with a significant portion attributed to preclinical testing. Organs-on-chips technology offers a promising solution to reduce these costs and improve the efficiency of drug discovery processes, driving its adoption across the pharmaceutical industry in North America.

Recent developments in the market have seen key players introducing innovative solutions and expanding their product offerings. In February 2024, Emulate Inc. announced the launch of a new multi-organ chip platform capable of simulating complex organ interactions, aimed at enhancing drug toxicity studies. Additionally, CN Bio Innovations reported in December 2023 a collaborative agreement with a major U.S. pharmaceutical company to develop custom organ-on-chip models for respiratory disease research, demonstrating the growing industry adoption of this technology in North America.

Asia Pacific

The Asia Pacific region is experiencing rapid growth in the organs-on-chips market, driven by increasing investment in life sciences research, rising demand for personalized medicine, and government initiatives to promote innovative healthcare technologies.

According to the Japan Agency for Medical Research and Development (AMED), the country invested approximately 146 billion yen (USD 1.3 Billion) in fiscal year 2022 for medical research and development, with a significant portion allocated to advanced biotechnologies like organs-on-chips. This substantial funding has catalyzed research activities and collaborations between academic institutions and industry players, fostering the adoption of organs-on-chips technology across the region.

The market's growth is further propelled by the region's large and diverse patient population, which presents unique opportunities for drug discovery and personalized medicine applications. China's National Medical Products Administration (NMPA) reported in 2023 that the country had over 5,000 new drug applications under review, highlighting the immense potential for organs-on-chips technology to streamline the drug development process. This has led to increased collaboration between local pharmaceutical companies and organs-on-chips developers to create more efficient and cost-effective drug screening methods.

Global Organs-On-Chips Market: Segmentation Analysis

The Global Organs-On-Chips Market is segmented on the basis of End-User, Application, Type, And Geography.

Organs-On-Chips Market, By End-User

Pharmaceutical and biotechnology companies
Academic
Research institutes

Based on the End-User, the Global Organs-On-Chips Market is segmented into Pharmaceutical and biotechnology companies, Academic, Research institutes. In the organs-on-chips market, pharmaceutical and biotechnology companies are the dominant end users, leveraging these technologies to enhance drug development processes and improve safety assessments. Meanwhile, the academic segment is experiencing rapid growth, fueled by increasing research initiatives and funding aimed at understanding complex biological systems. This trend underscores the importance of innovative educational tools in advancing scientific research and fostering collaboration between academia and industry.

Organs-On-Chips Market, By Application

Drug Discovery
Toxicology Research
Physiological Model
Others

Based on the Application, the Global Organs-On-Chips Market is segmented into Drug Discovery, Toxicology Research, Physiological Model, and Others. In the organs-on-chips market, the drug discovery segment is currently the dominant application, as it plays a crucial role in streamlining the drug development process and improving success rates. However, the toxicology research segment is experiencing rapid growth, driven by the increasing need for safer and more effective testing methods that reduce reliance on animal models. This shift reflects a broader trend toward regulatory compliance and ethical considerations in biomedical research.

Organs-On-Chips Market, By Type

Heart on chip
Human on chip
Intestine on chip
Kidney on chip
Liver on chip
Lung on chip

Based on Type, the Global Organs-On-Chips Market is segmented into Heart on chip, Human on chip, Intestine on chip, Kidney on chip, Liver on chip, and Lung on chip. In the organs-on-chips market, the liver on chip segment is currently dominating, driven by its critical role in drug metabolism and toxicity testing. However, the heart on chip segment is rapidly growing, fueled by increasing interest in cardiovascular disease research and personalized medicine applications. This trend highlights the rising demand for innovative models that can replicate complex organ functions for more accurate drug testing and development.

Organs-On-Chips Market, By Geography

North America
Europe
Asia Pacific
Rest of the World

Based on Geography, the Global Organs-On-Chips Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the organs-on-chips market, North America currently dominates due to its robust biotechnology sector and significant investments in research and development. However, the Asia Pacific region is emerging rapidly, driven by increasing government support for advanced biomedical technologies and a growing emphasis on personalized medicine. This shift indicates a strong potential for growth in Asia Pacific as it invests in innovative healthcare solutions.

Key Players

The "Global Organs-On-Chips Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
BiomimX SRL, Elveflow, Hesperos, Altis Biosystems, Nortis, Inc., AxoSim, Bi/ond, InSphero, Emulate, Inc., Allevi, Inc., MIMETAS BV, Netri, Valo Health (Tara Biosystems, Inc.), TissUse GmbH., MesoBiotech, Chiron, Cherry Biotech, 4Dcell, BioIVT, AlveoliX, BEOnchip, Tissue Dynamics.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Organs-On-Chips Market Key Developments

In August 2023, Emulate, Inc. announced the launch of its next-generation organ-on-chip platform, which offers enhanced predictive capabilities for drug response and toxicity testing, promising to accelerate drug development timelines.
In July 2023, researchers at MIT unveiled a novel multi-organ chip system that simulates human organ interactions more accurately, paving the way for improved disease modeling and personalized medicine applications.

1 INTRODUCTION OF GLOBAL ORGANS-ON-CHIPS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
3.5 Market attractiveness

4 GLOBAL ORGANS-ON-CHIPS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL ORGANS-ON-CHIPS MARKET, BY TYPE

5.1 Heart on chip
5.2 Human on chip
5.3 Intestine on chip
5.4 Kidney on chip
5.5 Liver on chip
5.6 Lung on chip

6 GLOBAL ORGANS-ON-CHIPS MARKET, BY APPLICATION

6.1 Drug discovery
6.2 Toxicology research
6.3 Physiological Model
6.4 Other applications

7 GLOBAL ORGANS-ON-CHIPS MARKET, BY END USER

7.1 Pharmaceutical and biotechnology companies
7.2 Academic
7.3 Research institutes

8 GLOBAL ORGANS-ON-CHIPS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL ORGANS-ON-CHIPS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies
9.4 ACE Matrix

10 COMPANY PROFILES

10.1 BiomimX SRL
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Elveflow
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Hesperos
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Altis Biosystems
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Nortis Inc.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 AxoSim
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Development
10.7 Bi/ond
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 InSphero
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Development
10.9 Emulate Inc.
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
10.10 Allevi Inc.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
10.11 MIMETAS BV
- 10.11.1 Overview
- 10.11.2 Financial Performance
- 10.11.3 Product Outlook
10.12 Netri
- 10.12.1 Overview
- 10.12.2 Financial Performance
- 10.12.3 Product Outlook
10.13 Valo Health (Tara Biosystems Inc.)
- 10.13.1 Overview
- 10.13.2 Financial Performance
- 10.13.3 Product Outlook
10.14 TissUse GmbH
- 10.14.1 Overview
- 10.14.2 Financial Performance
- 10.14.3 Product Outlook